Mingyu Pharmaceutical's Hong Kong IPO Application Lapses After Six Months

Stock News

05/26

Mingyu Pharmaceutical Co., Ltd. (referred to as Mingyu Pharmaceutical) has seen its Hong Kong stock exchange listing application lapse. The application, submitted on November 24, 2025, reached the end of its six-month validity period on May 24, 2026. At the time of submission, Morgan Stanley, BofA Securities, and CITIC Securities were acting as its joint sponsors.

According to the prospectus, Mingyu Pharmaceutical, founded in 2018, is a biotechnology innovation company. The company operates with a dual growth strategy: a robust clinical-stage oncology portfolio built upon its proprietary antibody-drug conjugate (ADC) platform and a novel PD-1/VEGF bispecific antibody (bsAb), alongside its own late-stage immunology assets advancing towards commercialization.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1105006085"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1105006085\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1105006085?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-26 11:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1105006085","market":"us","top_or_hot":-1,"title":"Mingyu Pharmaceutical's Hong Kong IPO Application Lapses After Six Months","media":"Stock News","content":"<p>Mingyu Pharmaceutical Co., Ltd. (referred to as Mingyu Pharmaceutical) has seen its Hong Kong stock exchange listing application lapse. The application, submitted on November 24, 2025, reached the end of its six-month validity period on May 24, 2026. At the time of submission, Morgan Stanley, BofA Securities, and CITIC Securities were acting as its joint sponsors.</p>\n<p>According to the prospectus, Mingyu Pharmaceutical, founded in 2018, is a biotechnology innovation company. The company operates with a dual growth strategy: a robust clinical-stage oncology portfolio built upon its proprietary antibody-drug conjugate (ADC) platform and a novel PD-1/VEGF bispecific antibody (bsAb), alongside its own late-stage immunology assets advancing towards commercialization.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mingyu Pharmaceutical's Hong Kong IPO Application Lapses After Six Months</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMingyu Pharmaceutical's Hong Kong IPO Application Lapses After Six Months\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2026-05-26 11:08</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Mingyu Pharmaceutical Co., Ltd. (referred to as Mingyu Pharmaceutical) has seen its Hong Kong stock exchange listing application lapse. The application, submitted on November 24, 2025, reached the end of its six-month validity period on May 24, 2026. At the time of submission, Morgan Stanley, BofA Securities, and CITIC Securities were acting as its joint sponsors.</p>\n<p>According to the prospectus, Mingyu Pharmaceutical, founded in 2018, is a biotechnology innovation company. The company operates with a dual growth strategy: a robust clinical-stage oncology portfolio built upon its proprietary antibody-drug conjugate (ADC) platform and a novel PD-1/VEGF bispecific antibody (bsAb), alongside its own late-stage immunology assets advancing towards commercialization.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01477","symbol_name":"歐康維視生物-B","start_time":0,"source_url":"","article_id":"1105006085","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1105006085","pubTimestamp":1779764902,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Mingyu Pharmaceutical Co., Ltd. (referred to as Mingyu Pharmaceutical) has seen its Hong Kong stock exchange listing application lapse. The application, submitted on November 24, 2025, reached the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01477":"欧康维视生物-B","SPCX":"SPAC and New Issue ETF","IPOS":"Renaissance International IPO ETF","VXUS":"国际股票ETF-Vanguard","BK4588":"碎股","BK1191":"制药","BK4585":"ETF&股票定投概念","BK1574":"生物医药B类股"},"translate_title":"明宇药业香港IPO申请半年后失效","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IPOS":1,"VXUS":1,"01477":1,"SPCX":1},"content_text":"Mingyu Pharmaceutical Co., Ltd. (referred to as Mingyu Pharmaceutical) has seen its Hong Kong stock exchange listing application lapse. The application, submitted on November 24, 2025, reached the end of its six-month validity period on May 24, 2026. At the time of submission, Morgan Stanley, BofA Securities, and CITIC Securities were acting as its joint sponsors.\nAccording to the prospectus, Mingyu Pharmaceutical, founded in 2018, is a biotechnology innovation company. The company operates with a dual growth strategy: a robust clinical-stage oncology portfolio built upon its proprietary antibody-drug conjugate (ADC) platform and a novel PD-1/VEGF bispecific antibody (bsAb), alongside its own late-stage immunology assets advancing towards commercialization.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}